Gabapentin use and a claim for memory loss in Wisconsin

Wisconsin has taken proactive regulatory action on gabapentin, classifying it as a Schedule V controlled substance — joining the small group of states that have acknowledged the drug's misuse and dependence potential. Wisconsin's manufacturing economy — dairy processing, paper mills, automotive parts, and heavy industry — produces chronic pain rates that drive substantial gabapentin prescribing. The state's opioid crisis hit northern and rural communities particularly hard, with gabapentin emerging as a primary alternative. The Medical College of Wisconsin and the University of Wisconsin Medical Center provide the state's primary neuroscience resources, but rural Wisconsin faces significant specialist shortages.

For the overall process and updates, read the Gabapentin use and a claim for memory loss overview. This page covers the local information available for Wisconsin.